Search Results - sergey+tarasov

3 Results

Sort By:

Synthetic lipopeptide inhibitors of RAS oncoproteins

Abstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the...

Published: 6/11/2024 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Vadim Gaponenko, Joseph Kates, Michael Dean, Alla Ivanova

Keywords(s): COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Cancer Therapeutic Agents that Bind to STAT Proteins

Abstract: The National Cancer Institute, Cancer and Inflammation Program seeks parties interested in collaborative research to further co-develop inhibitors of STAT proteins for the treatment of cancer. Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Olga Timofeeva, Vadim Gaponenko, Christopher Michejda, Alan Perantoni, Sergey Tarasov

Keywords(s): Autoimmune, N-terminal domain, STAT

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing, Application > Therapeutics

Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs

Abstract: Peptides corresponding to transmembrane domains of a number of integral proteins were discovered to spontaneously self-assemble in aqueous solutions into stable and remarkably uniform nanoparticles. Researchers at the NCI’s Cancer and Inflammation Program have developed fully synthetic, peptide-based, virus-like nanoparticles capable...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Christopher Michejda

Keywords(s): Drug Delivery, GPCR, Hydrophobic Agent, Nanoparticle, Peptide-based Nanoparticle, Synthetic Peptide, Tarasova, VIRUS-LIKE

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology